AYTU BIOPHARMA, INC
AYTU BIOPHARMA, INC
Insider Sentiment (TTM):
Last Purchase:2025-06-09Last Sale:-Shares Purchased (TTM):0Shares Sold (TTM):0
Institutional Sentiment:
As of:2026-03-31Institutional Shares Owned:3,797,462Shares Outstanding:10,511,583Institutional Ownership Pct.:36.13%
Earnings Market Reaction:
Filing Date:2026-05-13Price on Filing Date:N/APrevious Close:N/A% Change:N/A
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | |||||||||||||||||
Assets | |||||||||||||||||
Cash And Cash Equivalents At Carrying Value | 27 | 30 | 33 | 31 | 18 | 20 | 20 | 20 | 20 | 20 | 20 | 23 | |||||
Accounts Receivable Net Current | 24 | 31 | 33 | 31 | 36 | 25 | 23 | 24 | 30 | 29 | 30 | 29 | |||||
Inventory Net | 7 | 9 | 10 | 11 | 11 | 11 | 12 | 12 | 13 | 13 | 13 | 12 | |||||
Prepaid Expense Current | - | - | - | - | - | 6 | 6 | 6 | 7 | 8 | 7 | 7 | |||||
Prepaid Expense And Other Assets Current | 9 | 7 | 5 | 6 | 7 | - | - | 5 | - | - | - | - | |||||
Assets Of Disposal Group Including Discontinued Op… | - | - | - | 0 | 0 | 0 | 0 | 1 | - | - | - | - | |||||
Other Assets Current | - | - | - | - | - | 63 | 61 | 62 | 1 | 1 | 1 | 71 | |||||
Assets Current | 67 | 76 | 81 | 79 | 73 | - | - | 62 | 71 | 71 | 71 | 73 | |||||
Assets Noncurrent | |||||||||||||||||
Property Plant And Equipment Net | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | |||||
Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | |||||
Intangible Assets Net Excluding Goodwill | 42 | 44 | 41 | 42 | 49 | 50 | 51 | 52 | 54 | 56 | 57 | 59 | |||||
Other Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 3 | |||||
Disposal Group Including Discontinued Operation As… | - | - | - | 0 | 0 | 0 | 0 | 0 | - | - | - | - | |||||
Assets Noncurrent | 44 | 46 | 44 | 45 | 52 | 53 | 55 | 56 | 58 | 60 | 62 | 65 | |||||
Assets | 112 | 122 | 125 | 124 | 124 | 116 | 116 | 118 | 129 | 131 | 133 | 136 | |||||
Liabilities | |||||||||||||||||
Liabilities Current | |||||||||||||||||
Accounts Payable And Other Accrued Liabilities Cur… | - | - | - | - | - | - | - | - | - | - | 14 | 13 | |||||
Accounts Payable Current | 13 | 14 | 12 | 11 | 12 | 12 | 14 | 10 | 10 | 10 | - | 13 | |||||
Accrued Liabilities Current | 34 | 40 | 37 | 38 | 42 | 39 | 34 | 38 | 44 | 43 | 41 | 47 | |||||
Short Term Borrowings | - | - | - | - | - | 4 | 4 | 2 | 2 | 1 | 1 | 2 | |||||
Long Term Debt Current | - | - | - | - | - | 2 | 2 | 2 | 15 | 0 | - | 0 | |||||
Derivative Liabilities Current | - | - | - | - | - | - | - | - | 3 | - | - | - | |||||
Lines Of Credit Current | 10 | 9 | 15 | 9 | 10 | - | - | 2 | - | - | - | - | |||||
Long Term Debt And Capital Lease Obligations Curre… | 2 | 2 | 2 | 2 | 2 | - | - | 2 | - | - | 0 | 0 | |||||
Other Liabilities Current | 0 | 0 | 0 | 3 | 5 | 7 | 8 | 9 | 9 | 9 | 9 | 7 | |||||
Liabilities Of Disposal Group Including Discontinu… | - | - | - | 0 | 0 | 0 | 0 | 1 | - | - | - | - | |||||
Liabilities Current | 60 | 66 | 66 | 63 | 71 | 64 | 61 | 62 | 84 | 64 | 65 | 69 | |||||
Long Term Debt Noncurrent | - | - | - | - | - | 10 | 10 | 11 | 0 | 15 | - | 15 | |||||
Liabilities Noncurrent | |||||||||||||||||
Long Term Debt And Capital Lease Obligations | 10 | 10 | 10 | 11 | 10 | - | - | 11 | - | - | 15 | 15 | |||||
Derivative Liabilities Noncurrent | 2 | 27 | 20 | 26 | 4 | 6 | 9 | 13 | 9 | 13 | 12 | 6 | |||||
Other Liabilities Noncurrent | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 8 | 7 | |||||
Liabilities | - | - | - | - | - | - | - | - | - | - | 101 | 97 | |||||
Liabilities Noncurrent | 17 | 42 | 36 | 42 | 19 | 21 | 25 | 28 | 14 | 34 | - | 28 | |||||
Stockholders Equity | |||||||||||||||||
Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | |||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Additional Paid In Capital | 383 | 356 | 355 | 353 | 349 | 348 | 348 | 348 | 346 | 345 | 344 | 343 | |||||
Retained Earnings Accumulated Deficit | -348 | -342 | -332 | -334 | -314 | -318 | -318 | -320 | -315 | -312 | -312 | -304 | |||||
Stockholders Equity | 35 | 14 | 23 | 19 | 35 | 31 | 30 | 28 | 31 | 33 | 32 | 39 | |||||
Liabilities And Stockholders Equity | 112 | 122 | 125 | 124 | 124 | 116 | 116 | 118 | 129 | 131 | 133 | 136 | |||||
Preferred Stock Number Of… | |||||||||||||||||
Preferred Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Authorized | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | |||||
Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Number Of Sh… | |||||||||||||||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | |||||
Common Stock Shares Issued | 11 | 11 | 10 | 9 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | |||||
Shares Outstanding | 11 | 11 | 10 | 9 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
0/5
Search a metric to start building a table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
0/1
Search a metric to start building a visual
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 7.77% | 34.47% | 26.21% | -1.91% | -0.76% | -3.82% | 0.00% | -4.00% | - | - | - | - |
| 2025 | -5.71% | 1.71% | -4.57% | -10.07% | -25.90% | -5.76% | 48.15% | 76.30% | 77.78% | -8.76% | -16.73% | -8.37% |
| 2024 | -16.33% | -7.14% | -10.20% | -0.32% | 2.22% | -4.44% | -0.98% | -6.54% | -17.65% | -19.65% | -45.61% | -49.47% |
| 2023 | - | - | - | - | - | - | - | - | - | -7.35% | -25.24% | -9.27% |
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 50+ calculated metrics
Subscribe to unlock 17+ years of data and 50+ calculated metrics
Performance and Valuation Metrics
Metrics | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liquidity Ratios | |||||||||||||||||
| Current Ratio | 1.12 | 1.16 | 1.23 | 1.26 | 1.03 | - | - | 0.99 | 0.85 | 1.11 | 1.08 | 1.06 | |||||
| Quick Ratio | 0.85 | 0.93 | 1.00 | 0.98 | 0.76 | - | - | 0.71 | 0.61 | 0.78 | 0.77 | 0.78 | |||||
| Working Capital | 7.35M | 10.68M | 15.12M | 16.12M | 1.81M | - | - | -337.00K | -12.56M | 7.18M | 5.14M | 3.82M | |||||
Leverage & Debt | |||||||||||||||||
| Debt to Equity | 2.18 | 7.59 | 4.39 | 5.55 | 2.56 | 2.78 | 2.88 | 3.26 | 3.19 | 3.00 | 3.13 | 2.47 | |||||
| Interest Coverage TTM | -6.76 | -3.21 | -2.60 | -2.11 | -0.59 | -1.42 | -0.35 | -0.31 | 0.18 | -2.46 | -12.69 | - | |||||
| Debt Ratio | 0.69 | 0.88 | 0.81 | 0.85 | 0.72 | 0.74 | 0.74 | 0.77 | 0.76 | 0.75 | 0.76 | 0.71 | |||||
Efficiency & Turnover | |||||||||||||||||
| Asset Turnover TTM | 0.48 | 0.53 | 0.53 | 0.55 | 0.52 | 0.50 | 0.51 | 0.51 | 0.59 | 0.66 | 0.69 | 0.78 | |||||
| Days Sales Outstanding TTM | 194.48 | 164.10 | 161.55 | 150.33 | 182.25 | 162.87 | 151.39 | 146.89 | 143.55 | 111.39 | 108.13 | 86.07 | |||||
| Receivables Turnover TTM | 1.88 | 2.22 | 2.26 | 2.43 | 2.00 | 2.24 | 2.41 | 2.48 | 2.54 | 3.28 | 3.38 | 4.24 | |||||
Per Share Metrics | |||||||||||||||||
| Diluted EPS TTM | -3.24 | -2.44 | -0.67 | - | 0.20 | -0.62 | -0.69 | - | -2.47 | -3.26 | -4.46 | -5.11 | |||||
| Free Cash Flow Per Share TTM | 0.15 | -0.07 | -0.16 | -0.34 | -0.93 | 0.09 | -0.45 | -0.23 | 1.61 | 1.13 | 0.76 | -1.54 | |||||
| Dividend Per Share TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Margin Metrics | |||||||||||||||||
| Gross Profit Margin TTM | 64.78% | 66.84% | 67.56% | 69.04% | 70.82% | 71.95% | 75.07% | 75.26% | 69.56% | 65.48% | 63.18% | 62.04% | |||||
| Operating Profit Margin TTM | -26.79% | -13.85% | -13.19% | -11.79% | -3.76% | -10.58% | -2.59% | -2.44% | 0.86% | -6.96% | -16.69% | -15.89% | |||||
| Net Profit Margin TTM | -60.17% | -39.02% | -20.52% | -20.43% | 2.49% | -8.54% | -9.77% | -24.31% | -16.83% | -19.99% | -25.08% | -15.88% | |||||
Growth Metrics | |||||||||||||||||
| Net Revenue Growth (1Y) | -14.04% | 2.00% | -0.38% | 1.84% | -19.04% | -31.79% | -34.46% | -39.31% | -21.89% | -14.73% | -4.75% | 11.10% | |||||
| Net Income Growth (1Y) | -2,177.79% | 366.29% | 109.14% | -14.40% | -111.98% | -70.87% | -74.46% | -7.08% | -55.40% | -76.56% | -70.02% | -84.33% | |||||
| EPS Growth (1Y) | -1,312.61% | 184.90% | 34.42% | -24.51% | -110.80% | -73.79% | -76.93% | -43.96% | -69.96% | -86.79% | -86.23% | -86.20% | |||||
Valuation Metrics | |||||||||||||||||
| P/E TTM | -0.84 | -1.07 | -1.36 | -1.01 | 4.49 | -1.99 | -2.28 | -1.02 | -1.23 | -0.87 | -0.60 | -0.31 | |||||
| P/B TTM | 0.82 | 1.84 | 0.77 | 0.72 | 0.21 | 0.34 | 0.48 | 0.58 | 0.55 | 0.48 | 0.46 | 0.14 | |||||
| P/S TTM | 0.51 | 0.42 | 0.28 | 0.21 | 0.11 | 0.17 | 0.22 | 0.25 | 0.21 | 0.17 | 0.15 | 0.05 | |||||
| Market Cap | 28.70M | 26.09M | 17.75M | 13.69M | 7.36M | 10.42M | 14.26M | 16.17M | 16.82M | 15.67M | 14.80M | 5.34M | |||||
| Enterprise Value | 23.80M | 17.00M | 12.30M | 4.55M | 10.61M | 5.88M | 10.71M | 15.55M | 13.78M | 12.18M | 10.96M | -1.20M | |||||
Calculated Values | |||||||||||||||||
| Free Cash Flow TTM | 1.62M | -721.00K | -1.48M | -2.17M | -5.73M | 537.00K | -2.71M | -1.25M | 8.90M | 6.25M | 4.15M | -5.13M | |||||
| Net Debt | -4.90M | -9.10M | -5.45M | -9.14M | 3.25M | -4.55M | -3.55M | -625.00K | -3.04M | -3.49M | -3.85M | -6.54M | |||||
Per-Share and Margin | |||||||||||||||||
| EPS TTM | |||||||||||||||||
| Adjusted EPS TTM | |||||||||||||||||
| Cash Flow Per Share TTM | |||||||||||||||||
| Pretax Margin TTM | |||||||||||||||||
| Stock Comp to Revenue TTM | |||||||||||||||||
Turnover Ratios and Averages | |||||||||||||||||
| Average Assets | |||||||||||||||||
| Average Equity | |||||||||||||||||
| Average Inventory | |||||||||||||||||
| Average Receivables | |||||||||||||||||
| Average Accounts Payables | |||||||||||||||||
| Inventory Turnover TTM | |||||||||||||||||
| Payables Turnover TTM | |||||||||||||||||
| Days Inventory Outstanding TTM | |||||||||||||||||
| Days Payables Outstanding TTM | |||||||||||||||||
| Cash Conversion Cycle TTM | |||||||||||||||||
| Working Capital to Revenue | |||||||||||||||||
| Deferred Revenue to Revenue | |||||||||||||||||
Growth Rates | |||||||||||||||||
| Total Assets Growth (1Y) | |||||||||||||||||
| Total Assets Growth (3Y) | |||||||||||||||||
| Total Assets Growth (5Y) | |||||||||||||||||
| Dividends Paid Growth (1Y) | |||||||||||||||||
| Dividends Paid Growth (3Y) | |||||||||||||||||
| Dividends Paid Growth (5Y) | |||||||||||||||||
| EPS Growth (3Y) | |||||||||||||||||
| EPS Growth (5Y) | |||||||||||||||||
| Net Income Growth (3Y) | |||||||||||||||||
| Net Income Growth (5Y) | |||||||||||||||||
| Net Profit Margin Growth (1Y) | |||||||||||||||||
| Net Profit Margin Growth (3Y) | |||||||||||||||||
| Net Profit Margin Growth (5Y) | |||||||||||||||||
| Net Revenue Growth (3Y) | |||||||||||||||||
| Net Revenue Growth (5Y) | |||||||||||||||||
| Deferred Revenue Growth (1Y) | |||||||||||||||||
| Retained Earnings Growth (1Y) | |||||||||||||||||
Credit, Liquidity, Returns, Payout | |||||||||||||||||
| Cash Ratio | |||||||||||||||||
| Net Working Capital | |||||||||||||||||
| Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to Equity | |||||||||||||||||
| Altman A | |||||||||||||||||
| Altman B | |||||||||||||||||
| Altman C | |||||||||||||||||
| Altman D | |||||||||||||||||
| Altman E | |||||||||||||||||
| Altman Z-Score | |||||||||||||||||
| ROA TTM | |||||||||||||||||
| ROE TTM | |||||||||||||||||
| NOPAT TTM | |||||||||||||||||
| ROIC TTM | |||||||||||||||||
| Effective Tax Rate TTM | |||||||||||||||||
| Payout Ratio TTM | |||||||||||||||||
| Dilution Ratio | |||||||||||||||||
| Retained Earnings to Equity | |||||||||||||||||
| Treasury Stock to Equity | |||||||||||||||||
| Treasury Stock Change (1Y) | |||||||||||||||||
| Accrued to Current Liabilities | |||||||||||||||||
Valuation Ratios | |||||||||||||||||
| P/CF TTM | |||||||||||||||||
| Dividend Yield TTM | |||||||||||||||||
| Free Cash Flow Yield TTM | |||||||||||||||||
| EV EBITDA TTM | |||||||||||||||||
| EV EBIT TTM | |||||||||||||||||
| Stock Compensation TTM | |||||||||||||||||
| Adjusted Net Income TTM | |||||||||||||||||
| Billings TTM | |||||||||||||||||
| Total Debt | |||||||||||||||||
| Invested Capital | |||||||||||||||||
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
2025-06-09Purchase
Owner: Disbrow, Jarrett
Title: Chief Business Officer
Shares: 16,666
Price/Share: $1.50
Value: $24,999.00
Shares Owned: 29,462
Relationship: Officer
Ownership: Direct
2025-06-09Purchase
Owner: Disbrow, Joshua R.
Title: Chief Executive Officer
Shares: 66,666
Price/Share: $1.50
Value: $99,999.00
Shares Owned: 153,257
Relationship: Officer
Ownership: Direct
2025-02-28Purchase
Owner: Disbrow, Joshua R.
Title: Chief Executive Officer
Shares: 15,000
Price/Share: $1.30
Value: $19,500.00
Shares Owned: 86,591
Relationship: Officer
Ownership: Direct
2023-06-16Purchase
Owner: Pyszczymuka, Greg
Title: Chief Commerical Officer
Shares: 12,000
Price/Share: $1.87
Value: $22,440.00
Shares Owned: 21,935
Relationship: Officer
Ownership: Direct
2023-06-14Purchase
Owner: Disbrow, Joshua R.
Title: Chief Executive Officer
Shares: 14,000
Price/Share: $1.86
Value: $26,040.00
Shares Owned: 71,591
Relationship: Director,Officer
Ownership: Direct
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
No data available for chart
2026-03-31
36.13%
Inst. Shares: 3,797,462
Shares Outstanding: 10,511,583
2025-12-31
36.96%
Inst. Shares: 3,709,701
Shares Outstanding: 10,036,359
2025-09-30
37.81%
Inst. Shares: 3,570,026
Shares Outstanding: 9,441,073
2025-06-30
53.35%
Inst. Shares: 3,350,101
Shares Outstanding: 6,279,744
2025-03-31
60.70%
Inst. Shares: 3,723,958
Shares Outstanding: 6,134,634
AYTU BIOPHARMA, INC (AYTU) — SEC Financial Statements & Analysis
AYTU BIOPHARMA, INC (AYTU) is a pharmaceutical preparations company, incorporated in DE. AYTU BIOPHARMA, INC trades on Nasdaq as: AYTU. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), AYTU BIOPHARMA, INC reported a -14.04% year-over-year revenue growth, a Gross Profit Margin of 64.78% (TTM), a Debt-to-Equity ratio of 2.18x, a Price-to-Sales (P/S) ratio of 0.51x (TTM), a Price-to-Book (P/B) ratio of 0.82 (TTM), at a market cap of $28.70M. Figures below are sourced from SEC EDGAR, as-filed.
- Net Revenue TTM Growth 1Y
- -14.04%
- Gross Profit Margin TTM
- 64.78%
- Debt To Equity
- 2.18x
- P/S TTM
- 0.51x
- P/B TTM
- 0.82
- Market Cap
- $28.70M
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is AYTU BIOPHARMA, INC in?
AYTU BIOPHARMA, INC (AYTU) operates in the Pharmaceutical Preparations industry.
What is AYTU's market cap?
AYTU BIOPHARMA, INC (AYTU) has a market capitalization of $28.70M as of 2026-03-31.
What exchange does AYTU trade on?
AYTU BIOPHARMA, INC (AYTU) trades on the Nasdaq.
Where is AYTU BIOPHARMA, INC incorporated?
AYTU BIOPHARMA, INC is incorporated in DE.